Intellia Therapeutics
Clinical trials sponsored by Intellia Therapeutics, explained in plain language.
A gene-editing company using CRISPR technology to develop therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Editing shot aims to halt rare nerve disease in phase 3 trial Results expected Jul 2027 (estimated)
-
CRISPR therapy takes on rare swelling disorder
Disease control OngoingThis phase 3 trial tests a one-time gene editing treatment called NTLA-2002 for people with hereditary angioedema (HAE), a rare genetic condition causing sudden, painful swelling attacks. About 80 participants will receive either the treatment or a placebo. The goal is to see if …
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Gene therapy aims to stop painful swelling attacks in hereditary angioedema
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce h…
Phase 1/2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy for HAE: does it last? new study tracks Long-Term safety
Disease control By invitation onlyThis study follows about 100 people with hereditary angioedema who previously received the gene-editing therapy NTLA-2002. Researchers will monitor side effects and how well the treatment controls swelling attacks over time. The goal is to understand if a single dose can provide …
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene Editing's lasting impact: a Long-Term look at NTLA-2001
Knowledge-focused By invitation onlyThis study follows people who previously received NTLA-2001, an experimental gene-editing therapy, for a type of amyloidosis that can affect nerves or the heart. The goal is to monitor long-term safety and see if the therapy's effects on disease markers persist over time. Partici…
Sponsor: Intellia Therapeutics • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC